Tranexamic Acid Dosing in Adult Spinal Deformity Surgery
Adult Spinal Deformity
About this trial
This is an interventional treatment trial for Adult Spinal Deformity focused on measuring tranexamic acid, reconstructive spine surgery
Eligibility Criteria
Inclusion Criteria:
- Adult patients (ages 18-75) scheduled to undergo long segment (greater than 8 motion segments) posterior spinal fusion with instrumentation (PSF) for adult scoliosis
Exclusion Criteria:
- Patients with acquired defective color vision
- Subarachnoid hemorrhage
- Active intravascular clotting
- Hypersensitivity to tranexamic acid or any of the ingredients
- Patients who pre-donate autologous blood for intra- or post-operative use (Directed donor units are acceptable)
- History of suspected blood disorders or abnormal coagulation laboratory results
- Current anticoagulation therapy that cannot be interrupted
- History of deep vein thrombosis (DVT)
- Impaired renal function or creatinine clearance <60 ml/min
- Pregnancy or women who are lactating/breastfeeding
- Women on hormonal contraceptives
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High Dose/Study Group
Standard of Care/Control
Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.